Skip to main content

Unable to load price data. Sorry.


Nuvelo, Inc. (NASDAQ:NUVO.DL)

CAPS Rating: No stars

A biopharmaceutical company dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy.

Unable to load market data for this Ticker. Sorry.



This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

0 Outperform
0 Underperform

All-Star Players

0 Outperform
0 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ:NUVO.DL Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

xorg (< 20)
Submitted December 18, 2006

It took a bad drubbing, but its not a one trick pony ( yeah, main pony got clobbered ) Bayer isn't going tokiss their 50m investment goodbye yet. I suspect ( o.k. hope ) that the failure was due to a proceduralfailure rather than a drug failure given… More

majakblue (50.50)
Submitted March 31, 2007

Another biotech company that will never reach phase III trials. Predict management will within 3 years pull out whatever it can get and dump its stock. It probably did already. I predict that the stock will be worth less than a dollar a share within… More


  • Sector:
  • Industry:
  • Tags:

Recent Community Commentary

Read the most recent pitches from players about NUVO.DL.

No one has written a Pitch for NUVO.DL stock yet. Tell us why you think NUVO.DL will outperform or underperform against the market.


Find the members with the highest scoring picks in NUVO.DL.

No players have picked NUVO.DL yet. Tell us why you think NUVO.DL will outperform or underperform against the market.

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for NUVO.DL.